Acute respiratory infections are the leading cause of death and illness in children under 5
years old and represent a significant burden in older adults. Primarily caused by viruses …

DNA-based therapies are often limited by challenges such as stability, long-term integration,
low transfection efficiency, and insufficient targeted DNA delivery. This review focuses on …

The development of vaccines against RNA viruses has undergone a rapid evolution in
recent years, particularly driven by the COVID-19 pandemic. This review examines the key …

Hepatitis C is regarded as a global health issue caused by hepatitis C virus (HCV) infection.
HCV is targeted for elimination by 2030 as a global public health goal. However, the COVID …

Despite the great potential of DNA vaccines for a broad range of applications, ranging from
prevention of infections, over treatment of autoimmune and allergic diseases to cancer …

Vaccines represent a cornerstone in global health history, marking one of the most
significant scientific achievements. Initially consisting of live or attenuated microorganisms …

A vaccine for coccidioidomycosis is likely to undergo trials in the near future. In this paper,
we raise 4 questions that should be answered before its use and offer our solutions to these …

Messenger RNA (mRNA)-based immunotherapies and protein in situ production therapies
hold great promise for addressing theoretically all the diseases characterized by aberrant …

Cancer remains one of the global leading causes of death and various vaccines have been
developed over the years against it, including cell-based, nucleic acid-based, and viral …

Oligonucleotide therapeutics have the unique ability to address traditionally undruggable
targets through various target engagement pathways. However, despite advances in …